1Pengo V, de Caterina R. Prevention of thromboembolism in non-rheumatic atrial fibrillation: An update. Ital Heart J,2001, 2(9 Suppl) :972-979.
2Taylor F C, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with nonrheumatic atrial fibrillation. BMJ,2001, 322: 321--326.
3Koudstaal P J. Anticoagulants versus antiplatelet therapy for preventing stroke in patients With nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks. Cochrane Database Syst Rev, 2000,CD000187-- CD000187.
8Tan K T,Lip G Y.Atrial fibrillation:should wetarget platelets or the coagulation pathway [J].Card Electrophysiol Rev, 2003.7 : 370-371.
9Tan K T,Lip G Y.Atrial fibrillation:should wetarget platelets or the coagulation pathway.Card Electrophysiol Rev,2003,7:370-371.
10Tham LS,Goh BC,Nafziger A,et a.l Awarfarin-dosing model in Asians thatuses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9[J].Clin Pharmacol Ther,2006,80(4):346-355.
